Pharmaceutical - Hikma Pharmaceuticals


Current filters:

Hikma Pharmaceuticals

Popular Filters

Hikma first half EPS beats expectations; raises guidance


Jordan-headquartered drugmaker Hikma Pharmaceuticals (HIK: LSE) this morning (August 21) reported financial…

FinancialGenericsHikma PharmaceuticalsPharmaceutical

Hikma licenses Vibativ from Theravance for MENA region


Jordon-headquartered Hikma Pharmaceuticals (LSE: HIK) says it has signed an exclusive commercialization…

Antibiotics and Infectious diseasesHikma PharmaceuticalsLicensingPharmaceuticalRest of the WorldTheravanceVibativ

Hikma to retain its global Injectables business


Further to its announcement last month that it was undertaking a review of the strategic options for…

FinancialGenericsHikma PharmaceuticalsMergers & AcquisitionsPharmaceutical

Sinclair IS in Flammacerium deal with Hikma; sells Fazol G to Majorelle


UK specialty pharma firm Sinclair IS Pharma (AIM: SPH.L) and Jordon-headquartered Hikma Pharmaceuticals…

Antibiotics and Infectious diseasesFazol GHikma PharmaceuticalsLaboratoires MajorelleLicensingPharmaceuticalSinclair IS PharmaWomen's Health

Hikma delivers revenue growth of 21% and EPS up 24% for 2012


Jordon-headquartered Hikma Pharmaceuticals (LSE: HIK) has reported preliminary results for 2012, showing…

FinancialGenericsHikma PharmaceuticalsPharmaceutical

Hikma leaps as it confirms unsolicited interest in Injectables business


Jordanian drugmaker Hikma Pharmaceuticals (LSE: HIK) saw its shares jump 8.1% to£9.365 on Friday,…

FinancialGenericsHikma PharmaceuticalsMergers & AcquisitionsPharmaceutical

Hikma to buy Egyptian pharma company for around $20 million


Fast-growing Jordan-headquartered drugmaker Hikma Pharmaceuticals (LSE: HIK) says it has agreed to acquire…

Egyptian Company for Pharmaceuticals & ChemicGenericsHikma PharmaceuticalsMergers & AcquisitionsPharmaceuticalRest of the World

Solid first-half 2012 results from Jordan's Hikma


Fast-growing Jordan headquartered Hikma Pharmaceuticals (LSE: HIK) has reported its interim results for…

FinancialGenericsHikma PharmaceuticalsPharmaceutical

Hikma earnings down despite 25.6% revenue growth


Fast-growing Jordan headquartered drugmaker Hikma Pharmaceuticals (LSE: HIK) delivered what it called…

FinancialGenericsHikma PharmaceuticalsPharmaceutical

Hikma adds to stake in Promopharm; gets US appro for argatroban


Fast-growing Jordan headquartered Hikma Pharmaceuticals (LSE: HIK) says that it has increased its stake…

ArgatrobanCardio-vascularGenericsHikma PharmaceuticalsMergers & AcquisitionsNorth AmericaPharmaceuticalPromopharmRegulationRest of the World

AEterna Zentaris signs up Hikma to commercialize perifosine in MENA region


Canada’s AEterna Zentaris (TSX: AEZ) has signed an exclusive commercialization and licensing agreement…

AEterna ZentarisGenericsHikma PharmaceuticalsLicensingOncologyperifosinePharmaceuticalRest of the World

Hikma enters Moroccan market via $111 million controlling stake in Promopharm


Jordan-headquartered Hikma Pharmaceuticals (LSE: HIK) says that it has acquired 63.9% of Promopharm (Societe…

GenericsHikma PharmaceuticalsMergers & AcquisitionsPharmaceuticalPromopharmRest of the World

Jordan’s Hikma delivers 10.4% sales growth in first half 2011


Jordon-headquartered Hikma Pharmaceuticals (LSE: HIK) has reported interim results for the six months…

FinancialGenericsHikma PharmaceuticalsPharmaceutical

Company Spotlight



Back to top